Figure 2. Subgroup Analysis of the Primary Efficacy End Point in a Study of the Effect of Praliciguat on Peak Rate of Oxygen Consumption (V̇o2) in Patients With Heart Failure With Preserved Ejection Fraction.
The median peak V̇o2 was 12.6 mL/kg/min; mean age, 70.3 years; median left ventricular ejection fraction (LVEF), 61.5%; and median N-terminal fragment of brain natriuretic peptide (NT-proBNP), 232 ng/L. The analysis models were adjusted for the stratification factors and the baseline assessments.